Literature DB >> 35610994

The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610994      PMCID： PMC9122066     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.

Authors:  William J Sandborn; Subrata Ghosh; Julian Panes; Stefan Schreiber; Geert D'Haens; Satoshi Tanida; Jesse Siffledeen; Jeffrey Enejosa; Wen Zhou; Ahmed A Othman; Bidan Huang; Peter D R Higgins
Journal:  Gastroenterology       Date:  2020-02-22       Impact factor: 22.682

3.  A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.

Authors:  Subrata Ghosh; Tom Sensky; Francesc Casellas; Louis-Charles Rioux; Tariq Ahmad; Juan R Márquez; Tomas Vanasek; Irina Gubonina; Orhan Sezgin; Sandro Ardizzone; Kristina Kligys; Joel Petersson; Yasuo Suzuki; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2020-07-29       Impact factor: 9.071

Review 4.  The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.

Authors:  Jin-Woo Kim; Su-Young Kim
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923
  4 in total
  3 in total

1.  The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

Review 3.  Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.

Authors:  Maria Napolitano; Ferdinando D'Amico; Elisa Ragaini; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Drug Des Devel Ther       Date:  2022-06-17       Impact factor: 4.319
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.